Elevance Health (ELV) shares have rallied approximately 33.6% over the past year to a price of roughly US$410.95, prompting an analysis of whether the current valuation aligns with the company's earnings power. Management has reaffirmed its 2026 earnings and cost guidance, signaling continued commitment to profitability and expense discipline despite the recent stock appreciation. Valuation metrics indicate that Elevance Health trades at a P/E ratio of approximately 18.0x, which represents a discount compared to the broader Healthcare sector average of 24.0x and its peer group average near 26.8x. This pricing gap suggests the market is applying a more cautious multiple to the insurer relative to similar businesses, even as management maintains confident messaging regarding future profitability. Analyst narratives from Simply Wall St present a split view on the stock's fair value. The bull case argues that Elevance Health is 8% undervalued due to aggressive leveraging of advanced analytics, digitization, and AI-enabled tools designed to streamline clinical workflows and reduce fraud. Conversely, the bear case suggests the stock is roughly fairly valued, citing risks from elevated costs in government-backed plans and margin compression associated with a greater reliance on value-based care models.